Elvitegravir vs Raltegravir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV integrase · full HIV pipeline

Elvitegravir · Stribild

Marketed by Gilead Sciences and partners

Approved in HIVsmall molecule
Partial signal

NCT01095796 · Phase 3 · completed

Participants were randomized and quadruple-blinded to Stribild or active-controlled Atripla, with 348 and 352 treated participants analyzed, respectively. The primary week-48 virologic endpoint met the prespecified non-inferiority criterion, but HIV-1 RNA suppression is a surrogate endpoint rather than a hard clinical or endoscopic outcome.

Reported efficacy

The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1% (met)

Result source: NCT01095796

Raltegravir · Isentress

Marketed by Merck & Co.

Approved in HIVsmall molecule
Reliable signal

NCT00293254 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial with 351 patients, using HIV-1 RNA suppression - a regulator-accepted, disease-defining measure - as the primary endpoint. The raltegravir arm showed clearly higher suppression rates than placebo at both Week 16 and Week 48, with confidence intervals that do not overlap, indicating a statistically robust and clinically meaningful benefit.

Next expected readout: January 2028 · NCT02140255 (registry estimate)

Reported efficacy

Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks); Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 48 (48 Weeks); Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <400 Copies/mL (156 Weeks); Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <400 Copies/mL (240 Weeks): Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.3% (95% CI 71.3 to 82.6) vs Placebo + OBT 42.9% (95% CI 33.8 to 52.3) (met)

Result source: NCT00293254

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointElvitegravirRaltegravir
HIV-1 RNA below 50 copies/mL (week 48)87.6% vs 84.1%vs Atriplawk 48 · n 348NCT01095796
34 other results
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 93.1% vs 92.8% wk 48 · n 435 · Phase 3 · primary NCT01780506
  • 59% vs 57.8% wk 48 · n 351 · Phase 3 · primary NCT00708162
  • 93.8% vs 87.1% wk 48 · n 290 · Phase 3 · primary NCT01475838
  • 93.4% vs 88.1% wk 48 · n 290 · Phase 3 · primary NCT01495702
  • 89.5% vs 86.8% wk 48 · n 353 · Phase 3 · primary NCT01106586
  • 80.2% vs 75.3% wk 144 · n 348 · Phase 3 · secondary NCT01095796
  • 86.9% vs 83.1% wk 144 · n 435 · Phase 3 · secondary NCT01780506
  • 77.6% vs 74.6% wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 84.2% vs 81.5% wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 89.2% vs 88.2% wk 96 · n 435 · Phase 3 · secondary NCT01780506
  • 47.6% vs 45% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 52.4% vs 53% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 53.6% vs 56.4% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 86.9% vs 69.8% wk 96 · n 290 · Phase 3 · secondary NCT01475838
  • 86.6% vs 80.4% wk 96 · n 290 · Phase 3 · secondary NCT01495702
  • 83.3% vs 82.3% wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 85.9% vs 83.2% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 88.8% vs 85.5% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 59.8% vs 57.5% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 61% vs 60.7% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 86.1% vs 84.8% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 91.5% vs 88.5% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 76.1% vs 78.1% wk 192 · n 71 · Phase 3 · secondary NCT01095796
  • 78.4% vs 73.1% wk 192 · n 74 · Phase 3 · secondary NCT01106586
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · primary NCT00869557
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 89.6% vs 87% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 91.7% vs 82.6% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · secondary NCT00869557
—Not posted · NCT01195467
HIV-1 RNA 50 copies/mL or more (week 48)—Not reported—Not posted · NCT01195467
CD4 count, change (week 48)239 vs 206vs Atriplawk 48 · n 348NCT01095796
26 other results
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 235 vs 221 wk 48 · n 413 · Phase 3 · secondary NCT01780506
  • 138 vs 147 wk 48 · n 267 · Phase 3 · secondary NCT00708162
  • 56 vs 58 wk 48 · n 270 · Phase 3 · secondary NCT01495702
  • 295 vs 273 wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 60 vs 42 wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 40 vs 32 wk 48 · n 270 · Phase 3 · secondary NCT01475838
  • 207 vs 211 wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 285 vs 271 wk 96 · n 395 · Phase 3 · secondary NCT01780506
  • 205 vs 198 wk 96 · n 231 · Phase 3 · secondary NCT00708162
  • 61 vs 71 wk 96 · n 255 · Phase 3 · secondary NCT01475838
  • 83 vs 101 wk 96 · n 256 · Phase 3 · secondary NCT01495702
  • 256 vs 261 wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 321 vs 300 wk 144 · n 348 · Phase 3 · secondary NCT01095796
  • 323 vs 310 wk 144 · n 379 · Phase 3 · secondary NCT01780506
  • 280 vs 293 wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 360 vs 328 wk 192 · n 348 · Phase 3 · secondary NCT01095796
  • 338 vs 340 wk 192 · n 353 · Phase 3 · secondary NCT01106586
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 240 vs 166 wk 48 · n 45 · Phase 2 · secondary NCT00869557
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 161 vs 117 wk 24 · n 44 · Phase 2 · secondary NCT00869557
98.4 vs 39.8+58.6 vs placebo400 mg b.i.d. · wk 48 · n 217NCT00293254
6 other results
  • 120.2 vs 49.4 400 mg b.i.d · wk 48 · n 230 · Phase 3 · secondary NCT00293267
  • 157.2 vs 54.2 400 mg b.i.d. · wk 156 · n 189 · Phase 3 · secondary NCT00293254
  • 170.9 vs 71.0 400 mg b.i.d · wk 156 · n 207 · Phase 3 · secondary NCT00293267
  • 8.6 vs 21.9 wk 24 · n 19 · Phase 4 · primary NCT00772590
  • 2.7 vs 21.9 wk 24 · n 19 · Phase 4 · primary NCT00772590
  • 192 vs 205 wk 48 · n 9 · Phase 4 · primary NCT00762892

HIV-1 RNA below 50 copies/mL (week 48)

Elvitegravir
87.6% vs 84.1%vs Atriplawk 48 · n 348NCT01095796
34 other results
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 93.1% vs 92.8% wk 48 · n 435 · Phase 3 · primary NCT01780506
  • 59% vs 57.8% wk 48 · n 351 · Phase 3 · primary NCT00708162
  • 93.8% vs 87.1% wk 48 · n 290 · Phase 3 · primary NCT01475838
  • 93.4% vs 88.1% wk 48 · n 290 · Phase 3 · primary NCT01495702
  • 89.5% vs 86.8% wk 48 · n 353 · Phase 3 · primary NCT01106586
  • 80.2% vs 75.3% wk 144 · n 348 · Phase 3 · secondary NCT01095796
  • 86.9% vs 83.1% wk 144 · n 435 · Phase 3 · secondary NCT01780506
  • 77.6% vs 74.6% wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 84.2% vs 81.5% wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 89.2% vs 88.2% wk 96 · n 435 · Phase 3 · secondary NCT01780506
  • 47.6% vs 45% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 52.4% vs 53% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 53.6% vs 56.4% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 86.9% vs 69.8% wk 96 · n 290 · Phase 3 · secondary NCT01475838
  • 86.6% vs 80.4% wk 96 · n 290 · Phase 3 · secondary NCT01495702
  • 83.3% vs 82.3% wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 85.9% vs 83.2% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 88.8% vs 85.5% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 59.8% vs 57.5% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 61% vs 60.7% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 86.1% vs 84.8% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 91.5% vs 88.5% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 76.1% vs 78.1% wk 192 · n 71 · Phase 3 · secondary NCT01095796
  • 78.4% vs 73.1% wk 192 · n 74 · Phase 3 · secondary NCT01106586
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · primary NCT00869557
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 89.6% vs 87% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 91.7% vs 82.6% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · secondary NCT00869557
Raltegravir
—Not posted · NCT01195467

HIV-1 RNA 50 copies/mL or more (week 48)

Elvitegravir
—Not reported
Raltegravir
—Not posted · NCT01195467

CD4 count, change (week 48)

Elvitegravir
239 vs 206vs Atriplawk 48 · n 348NCT01095796
26 other results
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 235 vs 221 wk 48 · n 413 · Phase 3 · secondary NCT01780506
  • 138 vs 147 wk 48 · n 267 · Phase 3 · secondary NCT00708162
  • 56 vs 58 wk 48 · n 270 · Phase 3 · secondary NCT01495702
  • 295 vs 273 wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 60 vs 42 wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 40 vs 32 wk 48 · n 270 · Phase 3 · secondary NCT01475838
  • 207 vs 211 wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 285 vs 271 wk 96 · n 395 · Phase 3 · secondary NCT01780506
  • 205 vs 198 wk 96 · n 231 · Phase 3 · secondary NCT00708162
  • 61 vs 71 wk 96 · n 255 · Phase 3 · secondary NCT01475838
  • 83 vs 101 wk 96 · n 256 · Phase 3 · secondary NCT01495702
  • 256 vs 261 wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 321 vs 300 wk 144 · n 348 · Phase 3 · secondary NCT01095796
  • 323 vs 310 wk 144 · n 379 · Phase 3 · secondary NCT01780506
  • 280 vs 293 wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 360 vs 328 wk 192 · n 348 · Phase 3 · secondary NCT01095796
  • 338 vs 340 wk 192 · n 353 · Phase 3 · secondary NCT01106586
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 240 vs 166 wk 48 · n 45 · Phase 2 · secondary NCT00869557
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 161 vs 117 wk 24 · n 44 · Phase 2 · secondary NCT00869557
Raltegravir
98.4 vs 39.8+58.6 vs placebo400 mg b.i.d. · wk 48 · n 217NCT00293254
6 other results
  • 120.2 vs 49.4 400 mg b.i.d · wk 48 · n 230 · Phase 3 · secondary NCT00293267
  • 157.2 vs 54.2 400 mg b.i.d. · wk 156 · n 189 · Phase 3 · secondary NCT00293254
  • 170.9 vs 71.0 400 mg b.i.d · wk 156 · n 207 · Phase 3 · secondary NCT00293267
  • 8.6 vs 21.9 wk 24 · n 19 · Phase 4 · primary NCT00772590
  • 2.7 vs 21.9 wk 24 · n 19 · Phase 4 · primary NCT00772590
  • 192 vs 205 wk 48 · n 9 · Phase 4 · primary NCT00762892
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety

Coverage. Elvitegravir: 8 of 8 rows · Raltegravir: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricElvitegravir
Rows use multiple source trials
Raltegravir
Rows use multiple source trials
CD4+
absolute change · cells/uL
Extension (open-label)
265 vs 35 GEN cells/uLa,b,c
NCT01705574 · Phase 3 · registry result, not featured evidence
172.1 vs 54.1 placebo cells/uL @ 240wk400 mg b.i.d.a,b,c
NCT00293254 · Phase 3 · combination
1 other source trial
193.6 vs 68.2 placebo cells/uL @ 240wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
CD4+
absolute change · cells/uL
No placebo or comparator arm
229 cells/uL @ 48wkd,a,b
NCT01721109 · Phase 2/3 · registry result, not featured evidence
232 cells/uL @ 48wkd,a,b
NCT02131233 · Phase 3 · registry result, not featured evidence
HIV-1 RNA LT 40 Copies
responder rate · % of participants
No placebo or comparator arm
93.3% (n=223)e,a,b
NCT02397096 · Phase 3 · registry result, not featured evidence
show 3 more doses
93.3% (n=223) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
89.7% (n=447)
NCT02397096 · Phase 3 · registry result, not featured evidence
92.8% (n=447) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
81.5% (n=531) @ 96wka,b
NCT02131233 · Phase 3 · registry result, not featured evidence
HIV-1 RNA LT 50 Copies
responder rate · % of participants
No placebo or comparator arm
94.6% (n=223)e,f,g,b
NCT02397096 · Phase 3 · registry result, not featured evidence
show 3 more doses
94.6% (n=223) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
90.8% (n=447)
NCT02397096 · Phase 3 · registry result, not featured evidence
93.7% (n=447) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
90.6% (n=32) @ 96wkf,g,b
NCT00939874 · Phase 4 · registry result, not featured evidence
Dropout rate
83.6%h
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 38 more results
22.2%
NCT02477527 · Phase 4 · registry result, not featured evidence
—DSG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
6.3%Delayed Switch Group (DSG)
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 0-24
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
5.1%Immediate Switch Group (ISG)
NCT02397096 · Phase 3 · registry result, not featured evidence
5.1%E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3 · registry result, not featured evidence
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
20%E/C/F/TAF
NCT01797445 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3 · registry result, not featured evidence
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
5.4%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Double-Blind: E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
16%E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—Open-Label: E/C/F/TAF to E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
43.2%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
12.3%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
12.1%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
10.2%
NCT01475838 · Phase 3 · registry result, not featured evidence
—All Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
8.9%Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
—Stribild (Randomized Phase)
NCT01495702 · Phase 3 · registry result, not featured evidence
80.7%
NCT01106586 · Phase 3 · registry result, not featured evidence
0%
NCT01533259 · Phase 3 · registry result, not featured evidence
14%
NCT01721109 · Phase 2/3 · registry result, not featured evidence
5.3%
NCT01497899 · Phase 2 · registry result, not featured evidence
6.3%
NCT00869557 · Phase 2 · registry result, not featured evidence
23.7%400 mg b.i.d.i
NCT00293254 · Phase 3 · combination
show 27 more results
—400 mg b.i.d.
NCT00293254 · Phase 3 · combination
—400 mg b.i.d
NCT00293267 · Phase 3 · combination
17.5%400 mg b.i.d
NCT00293267 · Phase 3 · combination
25.5%400 mg b.i.d.
NCT00369941 · Phase 3
15.4%
NCT01147107 · Phase 4 · registry result, not featured evidence
9.5%
NCT03374358 · Phase 4 · registry result, not featured evidence
0%
NCT03667547 · Phase 4 · registry result, not featured evidence
—Arm A Raltegravir
NCT03205566 · Phase 4 · registry result, not featured evidence
—Arm B Raltegravir Lamivudine
NCT03205566 · Phase 4 · registry result, not featured evidence · combination
10.5%
NCT02383355 · Phase 4 · registry result, not featured evidence
38.5%
NCT00939874 · Phase 4 · registry result, not featured evidence
0%
NCT00843713 · Phase 4 · registry result, not featured evidence
22.2%
NCT01332227 · Phase 4 · registry result, not featured evidence · combination
27.3%
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
6.7%Switch to Tenofovir/Emtricitabine
NCT01270802 · Phase 4 · registry result, not featured evidence · combination
—Switch to Tenofovir/Emtricitabine/
NCT01270802 · Phase 4 · registry result, not featured evidence
35.7%
NCT00762892 · Phase 4 · registry result, not featured evidence
0%
NCT01335620 · Phase 4 · registry result, not featured evidence · combination
6.7%Intervention Arm No.1
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
28.6%Intervention Arm No.2
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
0%Hyper-immune Bovine Colostrum
NCT00772590 · Phase 4 · registry result, not featured evidence
0%Raltegravir + Hyper-immune Bovine
NCT00772590 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00631449 · Phase 4 · registry result, not featured evidence
7.5%1200 mg QD
NCT03029689 · Phase 3 · registry result, not featured evidence · combination
4.1%
NCT02284035 · Phase 3 · registry result, not featured evidence · combination
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
12.4%Reformulated Raltegravir
NCT02131233 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
2.5%h
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 38 more results
—
NCT02477527 · Phase 4 · registry result, not featured evidence
—DSG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
0.4%Delayed Switch Group (DSG)
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 0-24
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
1.6%Immediate Switch Group (ISG)
NCT02397096 · Phase 3 · registry result, not featured evidence
0.7%E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3 · registry result, not featured evidence
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
0.7%E/C/F/TAF
NCT01797445 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3 · registry result, not featured evidence
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
0.9%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Double-Blind: E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0.9%E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—Open-Label: E/C/F/TAF to E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
2.2%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
4.1%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
6.1%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
2%
NCT01475838 · Phase 3 · registry result, not featured evidence
—All Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
0.7%Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
—Stribild (Randomized Phase)
NCT01495702 · Phase 3 · registry result, not featured evidence
2.5%
NCT01106586 · Phase 3 · registry result, not featured evidence
—
NCT01533259 · Phase 3 · registry result, not featured evidence
—
NCT01721109 · Phase 2/3 · registry result, not featured evidence
0.9%
NCT01497899 · Phase 2 · registry result, not featured evidence
—
NCT00869557 · Phase 2 · registry result, not featured evidence
0.9%400 mg b.i.d.i
NCT00293254 · Phase 3 · combination
show 27 more results
—400 mg b.i.d.
NCT00293254 · Phase 3 · combination
—400 mg b.i.d
NCT00293267 · Phase 3 · combination
0.4%400 mg b.i.d
NCT00293267 · Phase 3 · combination
5%400 mg b.i.d.
NCT00369941 · Phase 3
—
NCT01147107 · Phase 4 · registry result, not featured evidence
—
NCT03374358 · Phase 4 · registry result, not featured evidence
—
NCT03667547 · Phase 4 · registry result, not featured evidence
—Arm A Raltegravir
NCT03205566 · Phase 4 · registry result, not featured evidence
—Arm B Raltegravir Lamivudine
NCT03205566 · Phase 4 · registry result, not featured evidence · combination
10.5%
NCT02383355 · Phase 4 · registry result, not featured evidence
—
NCT00939874 · Phase 4 · registry result, not featured evidence
—
NCT00843713 · Phase 4 · registry result, not featured evidence
5.6%
NCT01332227 · Phase 4 · registry result, not featured evidence · combination
—
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
0%Switch to Tenofovir/Emtricitabine
NCT01270802 · Phase 4 · registry result, not featured evidence · combination
—Switch to Tenofovir/Emtricitabine/
NCT01270802 · Phase 4 · registry result, not featured evidence
—
NCT00762892 · Phase 4 · registry result, not featured evidence
—
NCT01335620 · Phase 4 · registry result, not featured evidence · combination
0%Intervention Arm No.1
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
7.1%Intervention Arm No.2
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
—Hyper-immune Bovine Colostrum
NCT00772590 · Phase 4 · registry result, not featured evidence
—Raltegravir + Hyper-immune Bovine
NCT00772590 · Phase 4 · registry result, not featured evidence · combination
—
NCT00631449 · Phase 4 · registry result, not featured evidence
—1200 mg QD
NCT03029689 · Phase 3 · registry result, not featured evidence · combination
—
NCT02284035 · Phase 3 · registry result, not featured evidence · combination
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
1.3%Reformulated Raltegravir
NCT02131233 · Phase 3 · registry result, not featured evidence
Serious AEs
19.8%h
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 38 more results
0%
NCT02477527 · Phase 4 · registry result, not featured evidence
1.9%DSG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
6.4%DSG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
4.5%DSG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
2.3%DSG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
—Delayed Switch Group (DSG)
NCT02397096 · Phase 3 · registry result, not featured evidence
2.9%ISG Base Study Weeks 0-24
NCT02397096 · Phase 3 · registry result, not featured evidence
2.6%ISG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
9.3%ISG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
4.3%ISG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
3.6%ISG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
—Immediate Switch Group (ISG)
NCT02397096 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
3%Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3 · registry result, not featured evidence
5.2%Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3 · registry result, not featured evidence
8.2%Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF
NCT01797445 · Phase 3 · registry result, not featured evidence
12.5%E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3 · registry result, not featured evidence
2.8%Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3 · registry result, not featured evidence
1.7%Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3 · registry result, not featured evidence
5.3%DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
8.7%Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
9.1%
NCT02616783 · Phase 3 · registry result, not featured evidence
16.8%Double-Blind: E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0%Open-Label: E/C/F/TAF to E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
20.6%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
15.1%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
18.2%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
8.2%
NCT01475838 · Phase 3 · registry result, not featured evidence
8.9%All Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
—Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
8.2%Stribild (Randomized Phase)
NCT01495702 · Phase 3 · registry result, not featured evidence
16.4%
NCT01106586 · Phase 3 · registry result, not featured evidence
2.1%
NCT01533259 · Phase 3 · registry result, not featured evidence
10%
NCT01721109 · Phase 2/3 · registry result, not featured evidence
10.7%
NCT01497899 · Phase 2 · registry result, not featured evidence
4.2%
NCT00869557 · Phase 2 · registry result, not featured evidence
—400 mg b.i.d.i
NCT00293254 · Phase 3 · combination
show 27 more results
34.8%400 mg b.i.d.
NCT00293254 · Phase 3 · combination
41.8%400 mg b.i.d
NCT00293267 · Phase 3 · combination
—400 mg b.i.d
NCT00293267 · Phase 3 · combination
20.3%400 mg b.i.d.
NCT00369941 · Phase 3
21.1%
NCT01147107 · Phase 4 · registry result, not featured evidence
0%
NCT03374358 · Phase 4 · registry result, not featured evidence
0%
NCT03667547 · Phase 4 · registry result, not featured evidence
0%Arm A Raltegravir
NCT03205566 · Phase 4 · registry result, not featured evidence
0%Arm B Raltegravir Lamivudine
NCT03205566 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02383355 · Phase 4 · registry result, not featured evidence
13.5%
NCT00939874 · Phase 4 · registry result, not featured evidence
3.8%
NCT00843713 · Phase 4 · registry result, not featured evidence
5.6%
NCT01332227 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
—Switch to Tenofovir/Emtricitabine
NCT01270802 · Phase 4 · registry result, not featured evidence · combination
0%Switch to Tenofovir/Emtricitabine/
NCT01270802 · Phase 4 · registry result, not featured evidence
7.1%
NCT00762892 · Phase 4 · registry result, not featured evidence
0%
NCT01335620 · Phase 4 · registry result, not featured evidence · combination
13.3%Intervention Arm No.1
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
14.3%Intervention Arm No.2
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
0%Hyper-immune Bovine Colostrum
NCT00772590 · Phase 4 · registry result, not featured evidence
5.3%Raltegravir + Hyper-immune Bovine
NCT00772590 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00631449 · Phase 4 · registry result, not featured evidence
0%1200 mg QD
NCT03029689 · Phase 3 · registry result, not featured evidence · combination
6.1%
NCT02284035 · Phase 3 · registry result, not featured evidence · combination
9.6%1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
—Reformulated Raltegravir
NCT02131233 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
h
diarrhoea 26.7%
upper respiratory tract infection 26.4%
nausea 23%
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 31 more results
headache 6.7%
diarrhoea 4.3%
nasopharyngitis 4.3%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.4%
headache 6.4%
diarrhoea 5.4%
NCT02397096 · Phase 3 · registry result, not featured evidence
covid-19 3.9%
headache 1.9%
back pain 1.3%
NCT02397096 · Phase 3 · registry result, not featured evidence
covid-19 7%
arthralgia 0%
back pain 0%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.4%
headache 6.5%
diarrhoea 4.5%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.4%
back pain 3.7%
diarrhoea 3%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 12.8%
headache 5.5%
arthralgia 5.3%
NCT02397096 · Phase 3 · registry result, not featured evidence
back pain 2.3%
arthralgia 1.7%
nasopharyngitis 1.7%
NCT02397096 · Phase 3 · registry result, not featured evidence
covid-19 8.3%
arthralgia 1.2%
diarrhoea 1.2%
NCT02397096 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 7.4%
nasopharyngitis 5.2%
diarrhoea 4.4%
NCT01815736 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 6.1%
diarrhoea 5.2%
nasopharyngitis 4.7%
NCT01815736 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.5%
diarrhoea 11.4%
nasopharyngitis 10%
NCT01815736 · Phase 3 · registry result, not featured evidence
diarrhoea 23%
headache 22.7%
upper respiratory tract infection 20.2%
NCT01797445 · Phase 3 · registry result, not featured evidence
nasopharyngitis 3.5%
headache 2.8%
arthralgia 1.4%
NCT01797445 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.2%
cough 2.5%
syphilis 2.5%
NCT01797445 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 14.6%
headache 11%
anaemia 7.3%
NCT01705574 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.3%
headache 17%
nausea 14.9%
NCT01705574 · Phase 3 · registry result, not featured evidence
nasopharyngitis 10.9%
back pain 8.2%
diarrhoea 7.3%
NCT02616783 · Phase 3 · registry result, not featured evidence
diarrhoea 25.7%
upper respiratory tract infection 21.1%
nausea 16.8%
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
cough 4.4%
syphilis 4.4%
upper respiratory tract infection 3.3%
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
diarrhoea 33.9%
upper respiratory tract infection 21.2%
headache 13.8%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
upper respiratory tract infection 20.5%
nasopharyngitis 19.2%
bronchitis 13.7%
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 36.4%
insomnia 21.2%
headache 18.2%
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 13.3%
upper respiratory tract infection 9.9%
diarrhoea 9.2%
NCT01475838 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 11.3%
diarrhoea 10.2%
nasopharyngitis 10.2%
NCT01495702 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 11.3%
diarrhoea 10.3%
nasopharyngitis 10.3%
NCT01495702 · Phase 3 · registry result, not featured evidence
diarrhoea 28%
upper respiratory tract infection 24.4%
nausea 22.7%
NCT01106586 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 20.8%
insomnia 12.5%
anxiety 10.4%
NCT01533259 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 36%
headache 24%
vomiting 20%
NCT01721109 · Phase 2/3 · registry result, not featured evidence
nausea 22.3%
diarrhoea 17%
fatigue 16.1%
NCT01497899 · Phase 2 · registry result, not featured evidence
diarrhoea 27.1%
fatigue 16.7%
headache 14.6%
NCT00869557 · Phase 2 · registry result, not featured evidence
400 mg b.i.d.i
upper respiratory tract infection 33% (placebo 24.4%)
diarrhoea 32.6% (placebo 29.4%)
fatigue 19.6% (placebo 15.1%)
NCT00293254 · Phase 3 · combination
show 17 more results
400 mg b.i.d
diarrhoea 31.9% (placebo 28.8%)
nasopharyngitis 25% (placebo 17.8%)
bronchitis 18.1% (placebo 13.6%)
NCT00293267 · Phase 3 · combination
400 mg b.i.d.
nasopharyngitis 26.7%
headache 26%
diarrhoea 25.6%
NCT00369941 · Phase 3
alt elevation 55.3%
NCT01147107 · Phase 4 · registry result, not featured evidence
sleeping difficulties 52.6% (placebo 54.2%)
gastrointestinal (diarrhoea, nausea) 47.4% (placebo 29.2%)
headache 47.4% (placebo 33.3%)
NCT03374358 · Phase 4 · registry result, not featured evidence
runny nose 10.5%
cold 5.3%
diarrhoea 5.3%
NCT03205566 · Phase 4 · registry result, not featured evidence
nightmares and vivid dreams 13.2%
diarrhoea 7.9%
headache 7.9%
NCT03205566 · Phase 4 · registry result, not featured evidence · combination
headache 5.3%
insomnia 5.3%
NCT02383355 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 18.9%
diarrhoea 10.8%
abdominal cramps 5.4%
NCT00939874 · Phase 4 · registry result, not featured evidence
hyperbilirubinemia 3.8% (placebo 0%)
NCT00843713 · Phase 4 · registry result, not featured evidence
hyperbilirubinaemia 8.3%
ocular icterus 8.3%
bronchitis 5.6%
NCT01332227 · Phase 4 · registry result, not featured evidence · combination
gastrointestinal intolerance 9.1%
neuropsychiatric side effect 0%
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
neutropenia 6.7%
diastolic hypertension 0%
impaired fasting glucose 0%
NCT01270802 · Phase 4 · registry result, not featured evidence
bronchitis 20%
diarrhea 20%
headache 20%
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
diarrhea 21.4%
upper respiratory infection 21.4%
fatigue 14.3%
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
1200 mg QD
adverse event not related to the treatment 2.6% (placebo 5.6%)
NCT03029689 · Phase 3 · registry result, not featured evidence · combination
insomnia 8.2%
amigdalitis 6.1%
common cold 6.1%
NCT02284035 · Phase 3 · registry result, not featured evidence · combination
1200 mg QD + Truvada
headache 15.8%
nausea 13.6%
diarrhoea 13.4%
NCT02131233 · Phase 3 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dTrial phases differ: Phase 2/3 versus Phase 3.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fTrial phases differ: Phase 3 versus Phase 4.
  7. gPopulation context differs: registered conditions differ.
  8. hPopulation comparability has not been reviewed for 34 of these studies.
  9. iPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Elvitegravir

HIV-1 RNA Less Than 50 Copies 87.6% (n=348) vs 84.1% (n=352) Atripla @ 48wk
responder rate · % of participants
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 34 more results
84.2% (n=348) vs 81.5% (n=352) Atripla @ 96wk
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
80.2% (n=348) vs 75.3% (n=352) Atripla @ 144wk
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
76.1% (n=71) vs 78.1% (n=73) Atripla @ 192wk
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
85.9% (n=348) vs 83.2% (n=352) Atripla @ 48wk
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
88.8% (n=348) vs 85.5% (n=352) Atripla @ 48wk
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
92.8% (n=959) vs 89.1% (n=477) Baseline Treatment Regimen (SBR) @ 96wk
NCT01815736 · Phase 3 · registry result, not featured evidence
91.6% (n=431) vs 88.5% (n=435) E/C/F/TDF @ 48wk
NCT01797445 · Phase 3 · registry result, not featured evidence
84% (n=431) vs 82.3% (n=435) E/C/F/TDF @ 96wk
NCT01797445 · Phase 3 · registry result, not featured evidence
87.2% (n=289) vs 80.8% (n=286) ATV+RTV+TVD @ 48wk
NCT01705574 · Phase 3 · registry result, not featured evidence
93.1% (n=435) vs 92.8% (n=432) E/C/F/TDF @ 48wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
89.2% (n=435) vs 88.2% (n=432) E/C/F/TDF @ 96wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
86.9% (n=435) vs 83.1% (n=432) E/C/F/TDF @ 144wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
59% (n=351) vs 57.8% (n=351) Raltegravir @ 48wk
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
47.6% (n=351) vs 45% (n=351) Raltegravir @ 96wk
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
59.8% (n=351) vs 57.5% (n=351) Raltegravir @ 48wk
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
52.4% (n=351) vs 53% (n=351) Raltegravir @ 96wk
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
61% (n=351) vs 60.7% (n=351) Raltegravir @ 48wk
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
53.6% (n=351) vs 56.4% (n=351) Raltegravir @ 96wk
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
93.8% (n=290) vs 87.1% (n=139) PI+RTV+FTC/TDF @ 48wk
NCT01475838 · Phase 3 · registry result, not featured evidence
86.9% (n=290) vs 69.8% (n=139) PI+RTV+FTC/TDF @ 96wk
NCT01475838 · Phase 3 · registry result, not featured evidence
93.4% (n=290) vs 88.1% (n=143) NNRTI+FTC/TDF @ 48wk
NCT01495702 · Phase 3 · registry result, not featured evidence
86.6% (n=290) vs 80.4% (n=143) NNRTI+FTC/TDF @ 96wk
NCT01495702 · Phase 3 · registry result, not featured evidence
89.5% (n=353) vs 86.8% (n=355) ATV/r + FTC/TDF @ 48wk
NCT01106586 · Phase 3 · registry result, not featured evidence
83.3% (n=353) vs 82.3% (n=355) ATV/r + FTC/TDF @ 96wk
NCT01106586 · Phase 3 · registry result, not featured evidence
77.6% (n=353) vs 74.6% (n=355) ATV/r + FTC/TDF @ 144wk
NCT01106586 · Phase 3 · registry result, not featured evidence
78.4% (n=74) vs 73.1% (n=78) ATV/r + FTC/TDF @ 192wk
NCT01106586 · Phase 3 · registry result, not featured evidence
86.1% (n=353) vs 84.8% (n=355) ATV/r + FTC/TDF @ 48wk
NCT01106586 · Phase 3 · registry result, not featured evidence
91.5% (n=353) vs 88.5% (n=355) ATV/r + FTC/TDF @ 48wk
NCT01106586 · Phase 3 · registry result, not featured evidence
88.4% (n=112) vs 89.7% (n=58) E/C/F/TDF @ 24wk
NCT01497899 · Phase 2 · registry result, not featured evidence
88.4% (n=112) vs 87.9% (n=58) E/C/F/TDF @ 48wk
NCT01497899 · Phase 2 · registry result, not featured evidence
89.6% (n=48) vs 87% (n=23) Atripla @ 24wk
NCT00869557 · Phase 2 · registry result, not featured evidence
89.6% (n=48) vs 87% (n=23) Atripla @ 48wk
NCT00869557 · Phase 2 · registry result, not featured evidence
89.6% (n=48) vs 87% (n=23) Atripla @ 24wk
NCT00869557 · Phase 2 · registry result, not featured evidence
91.7% (n=48) vs 82.6% (n=23) Atripla @ 48wk
NCT00869557 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 50 95.2% (n=21) @ 24wk
event count · % of participants
No placebo or comparator arm
NCT02477527 · Phase 4 · registry result, not featured evidence · converted to % from 20 Participants as posted
LDL-C -16.54 mg/dL @ 24wk
absolute change · mg/dL
No placebo or comparator arm
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.94 mg/dL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
Non-HDL-C Change mg/dL -24.74 mg/dL @ 24wk
absolute change · mg/dL
No placebo or comparator arm
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.31 mg/dL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
CD4+ 13.9 cells/uL
absolute change · cells/uL
No placebo or comparator arm
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
show 3 more results
18 cells/uL
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
5.1 cells/uL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
18 cells/uL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Ge50 Copies 1.6% (n=447)
responder rate · % of participants
No placebo or comparator arm
NCT02397096 · Phase 3 · registry result, not featured evidence
show 1 more result
1.8% (n=223)
NCT02397096 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 97.2% (n=959) vs 93.1% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
All Participants
NCT01815736 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 20 Copies 93.5% (n=959) vs 90.4% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
All Participants
NCT01815736 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 20 Copies 90.6% (n=959) vs 85.3% (n=477) Baseline Treatment Regimen (SBR) @ 96wk
responder rate · % of participants
NCT01815736 · Phase 3 · registry result, not featured evidence
show 5 more results
82.4% (n=431) vs 80.7% (n=435) E/C/F/TDF @ 48wk
NCT01797445 · Phase 3 · registry result, not featured evidence
78.7% (n=431) vs 76.8% (n=435) E/C/F/TDF @ 96wk
NCT01797445 · Phase 3 · registry result, not featured evidence
86.4% (n=435) vs 87.3% (n=432) E/C/F/TDF @ 48wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
84.4% (n=435) vs 83.6% (n=432) E/C/F/TDF @ 96wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
84.6% (n=435) vs 80.1% (n=432) E/C/F/TDF @ 144wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
HIV-1 RNA Less Than 50 Copies 84.5% (n=278) @ 96wk
responder rate · % of participants
No placebo or comparator arm
NCT01705574 · Phase 3 · registry result, not featured evidence
show 11 more results
78.8% (n=33) @ 48wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
88.9% (n=33) @ 96wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
82.2% (n=73) @ 48wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
90.7% (n=73) @ 96wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
84.8% (n=33) @ 24wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
90.4% (n=73) @ 24wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
100% (n=48) @ 12wk
NCT01533259 · Phase 3 · registry result, not featured evidence
100% (n=48) @ 24wk
NCT01533259 · Phase 3 · registry result, not featured evidence
100% (n=48) @ 48wk
NCT01533259 · Phase 3 · registry result, not featured evidence
88% (n=50) @ 24wk
NCT01721109 · Phase 2/3 · registry result, not featured evidence
88% (n=50) @ 48wk
NCT01721109 · Phase 2/3 · registry result, not featured evidence
Lumbar Spine BMD 2.237% (n=102) vs -0.104% (n=54) Stay on Baseline Regimen @ 48wk
percent change · % of baseline
NCT02616783 · Phase 3 · registry result, not featured evidence
show 1 more result
1.625% (n=104) vs -0.027% (n=54) Stay on Baseline Regimen @ 24wk
NCT02616783 · Phase 3 · registry result, not featured evidence
Hip BMD 1.33% (n=101) vs -0.726% (n=54) Stay on Baseline Regimen @ 48wk
percent change · % of baseline
NCT02616783 · Phase 3 · registry result, not featured evidence
show 1 more result
0.808% (n=103) vs -0.537% (n=54) Stay on Baseline Regimen @ 24wk
NCT02616783 · Phase 3 · registry result, not featured evidence

+ 10 further endpoints in the CSV export.

Raltegravir

HIV RNA Less Than 400 Copies 77.3% (n=229) vs 42.9% (n=119) placebo @ 16wk400 mg b.i.d.
responder rate · % of participants
NCT00293254 · Phase 3 · combination
show 5 more results
71.1% (n=228) vs 37.8% (n=119) placebo @ 48wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
50.2% (n=229) vs 21% (n=119) placebo @ 156wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
77.7% (n=229) vs 41% (n=117) placebo @ 16wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
73.6% (n=231) vs 36.4% (n=118) placebo @ 48wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
57.3% (n=232) vs 25.6% (n=117) placebo @ 156wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV RNA Less Than 400 Copies 45.7% (n=230) vs 13.4% (n=119) placebo @ 240wk400 mg b.i.d.
responder rate · % of participants
Extension (open-label)
NCT00293254 · Phase 3 · combination
show 1 more result
45.3% (n=232) vs 20.3% (n=118) placebo @ 240wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV RNA Less Than 50 Copies 62% (n=229) vs 36.1% (n=119) placebo @ 16wk400 mg b.i.d.
responder rate · % of participants
NCT00293254 · Phase 3 · combination
show 5 more results
59.6% (n=228) vs 34.5% (n=119) placebo @ 48wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
47.6% (n=229) vs 17.6% (n=119) placebo @ 156wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
61.6% (n=229) vs 33.3% (n=117) placebo @ 16wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
64.5% (n=231) vs 31.4% (n=118) placebo @ 48wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
53.4% (n=232) vs 25.6% (n=117) placebo @ 156wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV RNA Less Than 50 Copies 41.3% (n=230) vs 13.4% (n=119) placebo @ 240wk400 mg b.i.d.
responder rate · % of participants
Extension (open-label)
NCT00293254 · Phase 3 · combination
show 1 more result
42.2% (n=232) vs 18.6% (n=118) placebo @ 240wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
Without Loss of Virologic 44.3% (n=230) vs 17.6% (n=119) placebo @ 156wk400 mg b.i.d.
responder rate · % of participants
NCT00293254 · Phase 3 · combination
HIV-1 RNA -1.92 vs -1.06 placebo copies/mL @ 16wk400 mg b.i.d.
absolute change · copies/mL
NCT00293254 · Phase 3 · combination
show 6 more results
-1.75 vs -0.87 placebo copies/mL @ 48wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
-1.37 vs -0.52 placebo copies/mL @ 156wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
-1.85 vs -0.78 placebo copies/mL @ 16wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
-1.67 vs -0.68 placebo copies/mL @ 48wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
-1.44 vs -0.51 placebo copies/mL @ 156wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
-3.05 vs -3.29 Atazanavir copies/mL @ 48wk
NCT00762892 · Phase 4 · registry result, not featured evidence
HIV-1 RNA -1.31 vs -0.41 placebo copies/mL @ 240wk400 mg b.i.d.
absolute change · copies/mL
Extension (open-label)
NCT00293254 · Phase 3 · combination
show 1 more result
-1.24 vs -0.45 placebo copies/mL @ 240wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV-1 RNA Less Than 400 Copies Per 86.1% (n=280) vs 81.9% (n=281) Efavirenz @ 48wk400 mg b.i.d.
event count · % of participants
NCT00369941 · Phase 3 · converted to % from 241 Participants as posted
show 7 more results
90% (n=280) vs 85.8% (n=281) Efavirenz @ 48wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 252 Participants as posted
81.1% (n=281) vs 78.7% (n=282) Efavirenz @ 96wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 228 Participants as posted
85.4% (n=281) vs 81.2% (n=282) Efavirenz @ 96wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 240 Participants as posted
75.4% (n=281) vs 68.1% (n=282) Efavirenz @ 156wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 212 Participants as posted
79.7% (n=281) vs 72% (n=282) Efavirenz @ 156wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 224 Participants as posted
71% (n=279) vs 61.3% (n=279) Efavirenz @ 240wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 198 Participants as posted
73.8% (n=279) vs 64.9% (n=279) Efavirenz @ 240wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 206 Participants as posted
CD4 189.1 vs 163.3 Efavirenz count @ 48wk400 mg b.i.d.
absolute change · count
NCT00369941 · Phase 3
show 3 more results
239.6 vs 224.8 Efavirenz count @ 96wk400 mg b.i.d.
NCT00369941 · Phase 3
331.7 vs 295.2 Efavirenz count @ 156wk400 mg b.i.d.
NCT00369941 · Phase 3
373.7 vs 311.6 Efavirenz count @ 240wk400 mg b.i.d.
NCT00369941 · Phase 3
Hepatic Fat Fraction 0.6 vs 0.3 placebo fraction @ 24wk
absolute change · fraction
NCT03374358 · Phase 4 · registry result, not featured evidence
Weight 2 vs 0.9 placebo kg @ 24wk
absolute change · kg
Change in body weight (24 weeks - baseline)
NCT03374358 · Phase 4 · registry result, not featured evidence
Body Fat Mass 1.5 vs -0.3 placebo kg @ 24wk
absolute change · kg
Change in body fat (24 weeks - baseline)
NCT03374358 · Phase 4 · registry result, not featured evidence

+ 17 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elvitegravir's landscape · Raltegravir's landscape